No means exist for predicting the acute respiratory distress syndrome (ARDS), which complicates sepsis, trauma, and a variety of clinical disorders. Because activation of phospholipid-signaling pathways involving the acyl chains oleate and linoleate may initiate and amplify the inflammatory response, and thereby lead to the development of ARDS, we examined whether serum concentrations of these bioactive lipids increase and are predictive of ARDS in at-risk patients.
Part I: A prospective, single-blind trial. Part II: A prospective, randomized, double-blind trial.
General intensive therapy units in five university teaching hospitals.
Part I: Thirty-nine healthy control patients were studied to determine normal distribution of serum acyl values, followed by 30 patients admitted with onset of sepsis, trauma, or development of ARDS (within 24 hrs of admission) over a 1-yr period. Part II: Eight patients admitted with sepsis syndrome over a 2-month period.
Part II: Patients were randomized to receive the substituted methylxanthine, lisofylline (CT1501R), or an identically presented placebo.
Measurements and Main Results
We measured the serum free fatty acid concentrations in the 39 healthy control subjects, and then we prospectively examined the serum free fatty acid concentrations in 30 age-matched patients in samples obtained within 24 hrs from the onset of sepsis, trauma, or development of ARDS. We then prospectively studied eight septic, at-risk patients who were matched for age, Acute Physiology and Chronic Health Evaluation II scores, Multiple Organ Failure Index, and Glasgow Coma Score, in a double-blind, placebo-controlled, pilot study. These patients included four patients who received no treatment and four patients who received lisofylline, a compound that decreases serum unsaturated free fatty acids and diminishes acute lung injury in animals caused by sepsis and/or trauma. The calculated ratios of serum free fatty acids (i.e., the ratio of C18 unsaturated fatty acids linoleate and oleate to fully saturated palmitate, C16:0) increased and predicted the development of ARDS in at-risk patients. Serum samples from the 30 patients, obtained within 24 hrs from the onset of sepsis, trauma, or development of ARDS, had significantly increased mean acyl chain ratios (1.42 plus minus 0.35 [SD]) compared with healthy control subjects (0.86 plus minus 0.25; p less than .01). Sera from 13 patients with sepsis or trauma who did not develop ARDS (group A [at-risk, non-pre-ARDS]) also had increased acyl ratios (1.23 plus minus 0.27) compared with sera from healthy control subjects (0.86 plus minus 0.25; p less than .01). Sera from seven patients who subsequently developed ARDS (group B [at-risk, pre-ARDS]) had higher acyl ratios (1.70 plus minus 0.21) than group A at-risk patients who did not develop ARDS (1.23 plus minus 0.27; p less than .01) or healthy control subjects (0.86 plus minus 0.25; p less than .001). Sera from ten group C patients with ARDS at the time of admission to the study had the highest acyl ratios (1.80 plus minus 0.75), which exceeded values for healthy control subjects (p less than .001) and group A at-risk patients without ARDS (p equals .01), but were not significantly different than group B at-risk, pre-ARDS patients (p equals .17). Prospective study of eight septic, at-risk patients demonstrated significantly (p less than .05) increased serum acyl ratios in the four untreated patients (findings consistent with the first study) but a significantly (p equals .02) reduced ratio in the four at-risk patients treated with lisofylline.
Increases in unsaturated serum acyl chain ratios differentiate between healthy and seriously ill patients, and identify those patients likely to develop ARDS. Thus, the serum acyl ratio may not only prospectively identify and facilitate the assessment of new treatments in patients at highest risk for developing ARDS, but may also lead to new insights about the pathogenesis of ARDS.
(Crit Care Med 1996; 24:1129-1136)